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Gender differences exist in the prevalence of glomerular diseases. Data based on histological diagnosis
underestimate the prevalence of preeclampsia, which is almost certainly the commonest glomerular
disease in the world, and uniquely gender-speciﬁc. Glomerular disease affects fertility via disease activity,
the therapeutic use of cyclophosphamide, and underlying chronic kidney disease. Techniques to preserve
fertility during chemotherapy and risk minimization of artiﬁcial reproductive techniques are considered.
The risks, beneﬁts, and effectiveness of different contraceptive methods for women with glomerular
disease are outlined. Glomerular disease increases the risk of adverse outcomes in pregnancy, including
preeclampsia; yet, diagnosis of preeclampsia is complicated by the presence of hypertension and pro-
teinuria that precede pregnancy. The role of renal biopsy in pregnancy is examined, in addition to the use
of emerging angiogenic biomarkers. The safety of drugs prescribed for glomerular disease in relation to
reproductive health is detailed. The impact of both gender and pregnancy on long-term prognosis is
discussed.
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I n a global survey of histological diagnoses ofglomerular disease, including more than 40,000 bi-
opsy results, 47% of diagnoses were made in women,
compared with 53% in men.1 Overall, female prepon-
derance was evident in both lupus nephritis and thin
basement membrane nephropathy, with a diagnosis of
IgA nephropathy being more commonly made in men.
Therefore, in regions where the incidence of lupus
nephritis was high, glomerular disease diagnoses
occurred more frequently in women than men. Gender
differences in systemic lupus erythematosus (SLE) are
greatest during reproductive age, with reported mal-
e:female ratios of 1:8 to 15, compared with ratios of 1:2
to 6 and 1:3 to 8 in prepubertal and postmenopausal
cohorts, respectively.2–4 The pathologic mechanisms
that underlie this gender disparity remain elusive,
although epigenetic and immunomodulatory effects of
endogenous sex hormones are hypothesized.4 Asian
and Hispanic women, as well as women of African
ancestry, have an additional risk of lupus nephritis
conferred by their ethnicity and race.5
A weakness of using histological diagnoses as a
measure of renal disease prevalence is that ﬁndings are
confounded by differences in renal biopsy threshold.
Where women have lower levels of proteinuria and
blood pressure,6 thresholds for biopsy may not be
reached and histological disease prevalence may not
reﬂect true population prevalence. Equally, glomerular
conditions that have clinical, rather than histological,
criteria for diagnosis will be omitted from any studies
based solely on biopsy data. Preeclampsia affects 3% to
5% of pregnancies,7 which means that it is estimated to
be the commonest glomerular disease in the world.
Pathognomonic renal changes include diffuse endo-
thelial swelling and vacuolation of podocytes (“endo-
theliosis”)8; however, preeclampsia is principally a
clinical diagnosis made on the basis of de novo hy-
pertension and proteinuria after 20 weeks’ gestation,
and renal biopsy is rarely required. Although pro-
teinuria that is either detected before 20 weeks’
gestation or persists postpartum warrants referral to
nephrology services for the exclusion of coexisting
renal disease9; preeclampsia is a glomerular disease that
is predominantly diagnosed and managed by obstetri-
cians,10 rather than nephrologists. The importance of
preeclampsia as a leading cause of glomerular pathol-
ogy in women is therefore underestimated by both
renal biopsy and nephrology referral data.
Depending on the health care setting, there may be
more opportunities for the diagnosis of asymptomatic
glomerular disease in women compared with men.
Gender differences in the utilization of primary care
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during the reproductive and mid-life years are recog-
nized, with higher rates of consultation by women than
by men.11 Reproductive health forms an important part
of this difference and attendances for contraception,
maternity, and postpartum care may include blood
pressure monitoring and urinalysis. It is, however,
important to recognize the potential pitfalls of such
opportunistic screening for glomerular disease; namely,
the assumption that proteinuria is not likely to be
glomerular in origin in a young woman.
Fertility
There are limited data about the effects of glomerular
disease on fertility. At the midpoint of the menstrual
cycle, there is positive feedback between estrogen and
the hypothalamic-pituitary axis, which leads to a surge
in luteinizing hormone (LH) and ovulation. Following
ovulation, the cells of the follicle form the corpus
luteum, which secretes progesterone in preparation for
implantation. If implantation does not occur, the
corpus luteum regresses and menstruation occurs. In
advanced chronic kidney disease (CKD), low levels of
estrogen confer negative feedback. Although levels of
LH are higher, there is no midcycle surge, and cycles
become anovulatory.12 Small cohort studies show that
there is progression from a regular menstrual cycle to
oligomenorrhea and amenorrhea as the severity of un-
derlying CKD increases, although levels of renal
dysfunction at which these changes become clinically
signiﬁcant, and the relative contribution from speciﬁc
glomerular disease pathologies, remain unknown.12
Contemporaneous European cohorts of women with
CKD due to different etiologies show that pregnancy
rates in transplant recipients and in patients requiring
dialysis are approximately 10% and 1%, respectively,
of those in the general population.12,13 The degree to
which this marked reduction in pregnancy in CKD is
due to reduced fertility rates or is confounded by
voluntary childlessness is unknown.
Of all glomerular pathologies, the effects of SLE on
female fertility are best described. Data on the impact
of other glomerulopathies on female fertility are
insufﬁcient to determine a disease-speciﬁc effect above
that of CKD. A cohort study of women receiving
fertility treatment led to an estimate that SLE contrib-
utes to 1% to 2% of infertility, which is higher than
expected given an estimated disease prevalence of 1 in
2000 adult women.14,15 In small cohorts of women with
lupus, menstrual irregularity has been found to corre-
late with levels of disease activity.16 Underlying
pathologic mechanisms are hypothesized to be multi-
factorial,15 including the effects of CKD on the men-
strual cycle, autoimmunity as evidenced by the
detection of anti–corpus luteum antibodies,17
endometriosis driven by altered immune function,18
and a reduced ovarian reserve associated with the
therapeutic use of cyclophosphamide.
Cyclophosphamide is an alkylating agent that causes
dose- and age-dependent gonadotoxicity, including
premature ovarian failure.19,20 Fertility preservation
should be considered before the use of cyclophospha-
mide in all premenopausal women. Pretreatment pres-
ervation of oocytes and gametes can be undertaken, but
this typically requires ovarian stimulation. Given that
the female predominance of lupus is hypothesized to be
due to the modulation of the immune system by sex
hormones, there is a concern that artiﬁcial ovarian
stimulation in lupus confers a risk of disease exacer-
bation and thrombosis, especially in the context of
circulating antiphospholipid antibodies. Published data
on the risks of ovarian stimulation are limited21,22 and
conﬂicting,22 and there is an absence of prospective
trials. Natural cycle oocyte retrieval negates the need
for ovarian stimulation and has been described in a
small cohort of 7 women with CKD, including 5 women
with lupus nephritis.23 However, this technique con-
tinues to be considered experimental, with insufﬁcient
outcome data. An alternative to preservation of repro-
ductive tissue is the use of LH-releasing hormone an-
alogs to inhibit ovarian function for the duration of
cyclophosphamide treatment. These are hypothesized
to preserve future fertility via a protective inhibition of
the hypothalamic-pituitary axis or a reduction in
ovarian blood supply and subsequent exposure to
cyclophosphamide. A small trial of 20 women with
lupus nephritis showed a reduction in premature
ovarian failure with the use of LH-releasing hormone
analogs.24 Larger randomized controlled trials25,26 and
meta-analysis data27 examining the use of LH-releasing
hormone analogs during cyclophosphamide treatment
for cancer demonstrate a safe and effective reduction in
premature ovarian failure.
Over recent decades, the prognosis for many
glomerular diseases has improved. With increasing
numbers of women achieving disease quiescence,21 and
social trends of increasing maternal age,28 the issue of
reproductive technology has become increasingly
relevant for women with glomerular disease. A recent
retrospective study of 97 cycles of in vitro fertilization
(IVF) in women with SLE and/or antiphospholipid
syndrome showed that IVF was safe and conferred
comparable pregnancy outcomes to the general popu-
lation. Lupus ﬂares and thrombotic events occurred in
only 8% of cycles, and half of these were attributed to
reduced concordance with treatment. However, it
should be noted that only 4 women in the study had
nephritis, maternal disease was quiescent or well
controlled in all women, and none had residual renal
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insufﬁciency.29 In addition to lupus disease ﬂare, a
concern with IVF in women with underlying renal
disease is the possibility of ovarian hyperstimulation,
which is associated with the overproduction of vaso-
active cytokines and inﬂammatory mediators leading to
intravascular ﬂuid loss, thromboembolism, and acute
kidney injury. A Cochrane review including 73 ran-
domized controlled trials demonstrated that IVF pro-
tocols that induce pituitary desensitization using
gonadotrophin-releasing hormone antagonists reduce
the incidence of ovarian hyperstimulation compared
with the prolonged use of gonadotrophin-releasing
hormone agonists.30 This is mirrored in small cohorts
of women with lupus and antiphospholipid syn-
drome.29 For this reason, IVF protocols using
gonadotrophin-releasing hormone antagonists should
be considered for all women with glomerular disease,
particularly lupus. In addition, single-embryo transfer
should be advised for women with underlying
glomerular disease due to the additive risks of adverse
pregnancy outcome conferred by multifetal pregnancy
at all stages of CKD.31,32
Contraception
Unplanned pregnancies occur throughout the spectrum
of renal disease. There is a paucity of contemporary
published data on contraception counseling and provi-
sion for women with glomerular disease. Older ques-
tionnaire data revealed that women with advanced CKD
are vulnerable to unintended pregnancy, as they are
sexually active in the absence of contraception, with
only a minority of women discussing contraceptionwith
their nephrologist.33 Even in transplant cohorts, in
whom contraceptive counseling is necessary due to the
need to avoid pregnancywithin the ﬁrst year, and in any
women taking teratogenic medication, between
one-third and one-half of pregnancies are un-
planned.34,35 A survey of 212 women with lupus
revealed that 46% had a risk of unintended pregnancy,
with 23% having unprotected sex “most of the time.”36
It is the experience of the authors that contraceptive
advice is often inadequate, despite the increased risk of
adverse pregnancy outcomes conferred by underlying
CKD.
The ideal contraceptive is effective, safe, and
acceptable to the patient and her partner. Effectiveness
rates should judged by the “typical”-use failure rates,
rather than presuming “perfect” use, as differences
exist (Table 1).37 For example, typical use of condoms
results in approximately 1 in 5 women falling pregnant
within a year of use, and they cannot therefore be
recommended as an effective long-term method for
preventing pregnancy. In contrast, long-acting
reversible contraceptive methods, including the intra-
uterine device (IUD) and the subdermal implant, have
“perfect”-use and “typical”-use failure rates that are
lower than that of female sterilization.
Estrogen-containing contraceptives include the
estrogen-containing (combined) pill, the vaginal ring,
and the contraceptive patch. All estrogen-based
methods confer an increased risk of hypertension,
venous thromboembolism, arterial disease, and breast
and cervical cancers. Whether this confers an unac-
ceptable absolute risk depends on a woman’s glomer-
ular disease etiology, cardiovascular risk factors, and
the burden of immunosuppressive therapy. Given that
lupus is hypothesized to be due to the modulation of
the immune system by sex hormones, there are con-
cerns that estrogen-containing agents may cause dis-
ease exacerbation or ﬂare, and estrogen-containing
contraceptives are contraindicated in lupus. Although
in a randomized controlled trial, women with stable
Table 1. Contraception in women with glomerular disease
Contraceptive method
Unintended pregnancy rate within
1st year of use (%)37
Contraindications in
glomerular disease Other considerationsPerfect use Typical use
Estrogen-containing methods
(pill, patch, ring)
0.3 9  Lupus
 VTE
 Vascular disease
 Breast cancer risk
 Cervical cancer risk with immunosuppression
 VTE risk in nephrotic syndrome
Progesterone-only pill 0.3 9  None  Longest re-dosing interval with desogestrel
(may improve typical use)
 Possible breast cancer risk, especially >40 yr
Progesterone IUD (Mirena) 0.2 0.2  None  Possible breast cancer risk, especially >40 yr
 Effective with immunosuppression,
no evidence of increased infection.
Progesterone implant (Nexplanon) 0.05 0.05  None  Possible breast cancer risk, especially >40 yr
Copper IUD 0.6 0.8  None  No associated hormonal risk
Male condom 2 18  Ineffective for long-term use  Protects against HIV and STI
Female condom 5 21
None 85 85
IUD, intrauterine device; STI, sexually transmitted infection; VTE, venous thromboembolism.
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disease who were lupus anticoagulant and anti-
cardiolipin antibody negative and with no history of
thromboses, there was no increased risk of ﬂare in the
those given the combined oral contraceptive (with 35
mg estradiol) compared with placebo.38 That study,
however, did not address women with proteinuria
>0.5 g per 24 hours. The risk of thromboembolism
means that any proteinuric glomerular disease is a
relative contraindication for estrogen-containing
methods, particularly now that more effective
nonestrogen-containing methods exist.
Progesterone-basedmethods of contraception include
the progesterone-only pill, the progesterone-containing
IUD (Mirena, Bayer, Whippany, NJ) and the subdermal
implant (Nexplanon, Merck & Co. Inc, Whitehouse
Station, NJ). These methods do not have the same risk
proﬁle as estrogen-containing methods and are appro-
priate for womenwith glomerular disease and CKD.9 The
theoretical risk of IUD failure due to inhibition of the
uterine inﬂammatory response by immunosuppressive
therapy is not borne out, with no evidence of excess IUD
failure following transplantation.39–41 There is also no
evidence of increased rates of IUD-associated pelvic
infection in cohorts of immunosuppressed women.40,42
Studies of breast cancer risk in women using hor-
monal methods of contraception are inconsistent in their
ﬁndings. A recent large prospective population study of
1.8millionwomen revealed a 20% increased relative risk
of breast cancer in women using estrogen-containing or
progesterone-only methods of contraception, but the
absolute increase in riskwas just 2 per 100,000 inwomen
younger than 35 years.43 This very low absolute risk
must be weighed against beneﬁts in preventing un-
planned pregnancy, as well as reducing rates of ovarian,
endometrial, and colorectal cancer.44 Nonhormonal
methods of contraception (e.g., copper IUD) should be
considered for women older than 40 years.
Pregnancy
As with all aspects of glomerular disease in women, the
pregnancy literature is dominated by SLEwith a paucity
of data on other primary glomerulonephropathies. A
systematic review45 and meta-analysis data46 show
increased rates of adverse pregnancy outcomes in
women with lupus, including preeclampsia (7.6%, RR:
1.91), fetal growth restriction (12.7%, relative risk [RR]:
1.69), preterm delivery (39.4%, RR 3.05), and pregnancy
loss due to spontaneous abortion (16.0%, RR: 1.51),
neonatal death, and stillbirth (2.5%–3.6%, RR: 1.70).
Active lupus nephritis is a signiﬁcant risk factor for the
development of maternal hypertension and preterm
delivery,45,47 and whenever possible, pregnancy should
be delayed until disease is quiescent on stable treatment
for at least 6 months. However, even a history of lupus
nephritis is associated with an increased risk for devel-
opment of preeclampsia.45 Other risk factors for the
development of pregnancy complications in lupus
include black race48 and Hispanic49 ethnicity, chronic
hypertension,50 and the degree of proteinuria.51 The
presence of lupus anticoagulant antibodies is a strong
predictor of adverse pregnancy outcome in lupus (RR:
8.32; conﬁdence interval: 3.59–19.26),49 and the pres-
ence of antiphospholipid antibodies correlates with rates
of hypertension, preterm birth, and pregnancy loss in
lupus nephritis.45 However,mostwomenwith quiescent
lupus and normal renal function have good pregnancy
outcomes.49
Published literature regarding the risks of a ﬂare of
lupus in pregnancy are conﬂicting, with signiﬁcant
heterogeneity in disease deﬁnition and the level of pre-
pregnancy disease activity. A retrospective study of
113 pregnancies in 81 women with lupus nephritis
showed a renal ﬂare in 15% of women during preg-
nancy, as well as in 15% of women within the ﬁrst
postpartum year. This is supported by meta-analysis,
which reveals a lupus ﬂare attributable to pregnancy
in 26% of women, with nephritis complicating 16% of
pregnancies.45
The management of lupus nephritis in pregnancy
begins pre-pregnancy, with the requirement for disease
stability on “pregnancy-safe” medication (see later in
this article). Hydroxychloroquine is safe in preg-
nancy,52,53 reduces steroid exposure,54 prevents disease
ﬂare,55 and is associated with a decrease in fetal growth
restriction.56 It should therefore be used during preg-
nancy in all women with a history of lupus
nephritis.51,57,58 For women with Sjögren syndrome
antigen antibodies SSA (Ro) and SSB (La), there is a risk
of placental transfer to the fetus, which confers a 2% to
5% risk of congenital heart block and a 15% to 16%
risk of cutaneous lupus.59,60 There is evidence that
maternal hydroxychloroquine reduces the risk of
congenital heart block in women with a previous
affected child,61 and a reduced frequency of congenital
heart block is reported in cohorts with high levels of
hydroxychloroquine use.49 In the absence of better
evidence, these data are used to support its use during
pregnancy for primary prevention of congenital heart
block in women with SSA/SSB antibodies. All women
with connective tissue diseases should be screened for
these antibodies and, if present, should be offered se-
rial fetal echocardiography from 16 weeks, although
the cost-effectiveness of this in women without pre-
vious affected pregnancies is unclear.62 Thrombotic
risk should be assessed by maternal antiphospholipid
antibody status and quantiﬁcation of proteinuria in
addition to standard criteria. Low molecular weight
heparin prophylaxis may be indicated, although there
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is insufﬁcient evidence (and consensus) as to the level
of proteinuria at which the maternal thromboembolic
risk becomes clinically signiﬁcant. The authors suggest
that prophylaxis is considered for pregnant women
with a protein:creatinine ratio >250 mg/mmol. Low
molecular weight heparin is also indicated during
pregnancy for all women with a history of thrombotic
or obstetric complications in association with anti-
phospholipid antibodies. Although there is a strong
association between lupus anticoagulant and adverse
pregnancy outcome,49 there are no outcome data to
support the use of heparin above that of antiplatelet
agents alone in women without previous complica-
tions63; however, there remain inherent difﬁculties in
assessing the clinical signiﬁcance of antiphospholipid
antibodies in women with lupus nephritis, especially in
primiparous women who have no pregnancy history to
inform risk assessment. Whether low molecular weight
heparin confers additional beneﬁt to the standard use
of aspirin in women with lupus nephritis who are
positive for lupus anticoagulant remains unknown. The
clinical distinction between lupus ﬂare and pre-
eclampsia is difﬁcult given the degree of phenotypic
overlap, which includes proteinuria, hypertension,
thrombocytopenia, and hemolysis. Although hematu-
ria, quantiﬁcation of complement, the presence of other
distinguishing systemic features, and the use of
angiogenic biomarkers (see later in this article) may
increase diagnostic speciﬁcity, surveillance in preg-
nancy should be by an expert, multidisciplinary team.
The paucity of disease-speciﬁc data for nonlupus
glomerular disease was revealed in a systematic review
in 2017.58 IgA nephropathy was most commonly
reported in the literature, with 12 studies including a
total of 867 pregnancies. In contrast, there are only 2
studies of membranous nephropathy in pregnancy,
including 70 pregnancies in 42 women. Although the
M-type phospholipase A2 receptor is the major recog-
nized antigen in membranous nephropathy, data in
pregnancy regarding the prognostic and diagnostic
utility of anti–phospholipase A2 receptor are limited to
an isolated case study of successful pregnancy
outcome.64 Regardless of the glomerular disease etiol-
ogy, consistent themes include the association of
adverse pregnancy outcome with worsening renal
function, maternal hypertension, and increasing levels
of proteinuria.58
Management of nonlupus glomerulopathy in preg-
nancy is “generic” rather than disease-speciﬁc. The
importance of disease control in relapsing-remitting
glomerular disease is based on the presumption that
data from lupus51 and vasculitis65 cohorts are general-
izable.58 Blood pressure management is a priority for all
glomerular disease, and there is increasing consensus
that a blood pressure target of <140/90 mm Hg is
appropriate for pregnancy.9 A recent large randomized
controlled trial in women without CKD provides evi-
dence that tighter control of blood pressure during
pregnancy does not compromise fetal growth, but does
reduce episodes of severe hypertension (>160/110
mm Hg) that would be considered harmful in nonpreg-
nant CKD.66 Angiotensin-converting enzyme inhibitors
and angiotensin receptor antagonists are fetotoxic (see
later in this article) and are contraindicated in preg-
nancy, although there are limited data from single-arm
studies, which suggest a pre-pregnancy beneﬁt. Small
studies of women with diabetic nephropathy suggest
that pre-pregnancy blood pressure control and minimi-
zation of proteinuria with angiotensin blockade offers
beneﬁt for pregnancy outcome,67,68 which becomes
comparable with women without proteinuria.69 Low-
dose aspirin (75–150 mg) has been shown in a large
meta-analysis to reduce the risk of preeclampsia, fetal
growth restriction, and preterm birth in women at
elevated risk of preeclampsia,70 and is indicated from 12
weeks’ gestation for all women with glomerular disease,
regardless of CKD stage.10 Calcium supplementation also
has been shown to reduce the risk of preeclampsia.Meta-
analyses of heterogeneous data reveal a reduction in
preeclampsia with supplementation of calcium>1 g per
day, particularly in women known to be at high risk of
preeclampsia, and in those with low dietary calcium
intake.71,72 High-dose calcium supplementation should,
however, be avoided in women with renal dysfunction
causing secondary hyperparathyroidism.
The Diagnosis of Preeclampsia
There is an increased risk of preeclampsia conferred by
all stages of CKD,73 which increases proportionally with
renal disease severity.32,74 Preeclampsia leads to
maternal and fetal morbidity and mortality. It is a key
component of adverse pregnancy outcome in CKD,
leading to fetal growth restriction and iatrogenic pre-
term delivery. Although symptoms may be ameliorated,
the disease course is unpredictable, and the only cure is
delivery. The underlying pathophysiology is believed to
be an abnormal vascular response to impaired placen-
tation, leading to multisystem clinical features,
including cerebral, hepatic, hematological, renal, and
fetal disease. The balance between circulating angio-
genic (placental growth factor) and anti-angiogenic
markers (soluble fms-like tyrosine kinase) has been
found to be altered in women with preeclampsia, with
low levels of placental growth factor and high levels of
soluble fms-like tyrosine kinase predicting the devel-
opment of preeclampsia75 and the need for delivery.76
The diagnosis of preeclampsia is made with the
development of de novo hypertension and proteinuria
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after 20 weeks’ gestation. Such diagnostic criteria are
redundant in women with glomerular disease who have
hypertension or proteinuria, or both, that predates
pregnancy. The diagnosis of superimposed preeclampsia
in women with glomerular disease is therefore difﬁcult,
with no standard diagnostic criteria, and the potential
for harm due to both under- and overdiagnosis. There
are limited data on the predictive and diagnostic utility
of angiogenic biomarkers in women with glomerular
disease, but isolated cohort studies have shown useful
discrimination for superimposed preeclampsia inwomen
with chronic hypertension or CKD using placental
growth factor less than the ﬁfth centile in the prediction
of delivery within 14 days (negative predictive value
95.5% [95% conﬁdence interval: 89.9–98.5]) in a test
cohort and 91.1% [95% conﬁdence interval: 82.6–96.4]
in a validation cohort),77 in addition to a high negative
predictive value in ruling out adverse pregnancy out-
comes in lupus.78 More data are needed for interpreta-
tion of these biomarkers in women with advanced renal
dysfunction.77,79
Biopsy
Renal biopsy is indicatedwhen the beneﬁt of obtaining a
histological diagnosis outweighs the risk of the proced-
ure. This risk-beneﬁt proﬁle is modiﬁed by female
reproductive health, which warrants particular consid-
eration (Table 2). For women with lupus nephritis
contemplating pregnancy, the threshold for biopsy is
potentially reduced. Due to the risks of adverse preg-
nancy outcome conferred by active disease, this should
be excluded or managed before pregnancy, and the
value of histological conﬁrmation of disease quiescence
should be considered even in the context of low-grade
proteinuria and stable renal function, especially if
medication needs to be modiﬁed before pregnancy.
A systematic review of 197 renal biopsies performed
during pregnancy revealed a signiﬁcantly higher
complication rate (7%) for biopsies performed in
pregnancy, compared with those performed post-
partum (1%).80 Major bleeding complications were
seen in 2% of women, during gestational weeks 23 to
26. Although this study included biopsies taken over a
long period (1965–2010), there was no clear trend of a
reduction in risk with time. Hypothesized factors
contributing to biopsy complications during preg-
nancy include both the physiological increase in renal
blood ﬂow, and the gravid uterus preventing biopsy in
the usual prone position. A recent retrospective study
showed that biopsy during pregnancy is relatively
rare, with only 1% (19/1399) of renal biopsies in
women aged 16 to 49 years performed during preg-
nancy.81 However, renal biopsy leads to a change in
therapeutic management in 66% of pregnant women,80
highlighting the importance of a histological diagnosis
in informing the management of glomerular disease in
pregnancy. The major indication for renal biopsy
during pregnancy is a de novo presentation of apparent
glomerular disease in early pregnancy when bleeding
risk appears lower, and when a diagnosis would guide
therapy. Once the pregnancy reaches beyond 30 weeks’
gestation, the increased risks of renal biopsy are un-
likely to outweigh the beneﬁts of continuing the
pregnancy before proceeding to a lower-risk renal bi-
opsy in the postpartum period. Corticosteroids given at
this stage for fetal lung maturation may have additional
maternal beneﬁt in steroid-sensitive glomerular disease.
The discrimination between glomerular disease and
preeclampsia may be more safely resolved by emerging
biomarkers, including placental growth factor, soluble
fms-like tyrosine kinase, and anti–phospholipase A2
receptor, rather than biopsy.
Biopsy is more commonly performed in the post-
partum period than in pregnancy.81 It is advised to
wait for at least 6 weeks for both the clinical and his-
tological features of preeclampsia to regress before
assessing the need for biopsy for primary glomerular
disease in postpartum women, unless there is clinical
suspicion of active or rapidly progressive glomerular
disease, in which case biopsy should be done urgently.
A retrospective study of 154 biopsies performed within
a year of pregnancy in the United Kingdom revealed
that the most common diagnosis was focal segmental
glomerulosclerosis made in 32% of women, compared
with 10% of matched controls. It is difﬁcult conclude
whether this highlights the “unmasking” of asymp-
tomatic renal disease by pregnancy, or the detrimental
effect of pregnancy-induced hyperﬁltration in women
with underlying glomerular dysfunction. The most
common diagnosis in women biopsied without rela-
tionship to pregnancy was lupus nephritis, which was
diagnosed in 24% of women, compared with 14% in
pregnancy. This allows the presumption that most
pregnant women already had a prior diagnosis of
lupus, meaning that treatment could be instigated in
pregnancy without repeat biopsy.
Table 2. The impact of reproductive health on indications for renal
biopsy in women with glomerular disease
Time of biopsy Biopsy factors speciﬁc to reproductive health
Pre-pregnancy  Ensures disease quiescence in relapsing-remitting glomerular
disease to optimize future pregnancy outcome.
Pregnancy  To facilitate diagnosis of glomerular disease in pregnancy, where
histological diagnosis will alter management.
 Increased risk of bleeding in meta-analysis (second trimester).
Postpartum  Increased prevalence of focal segmental glomerulosclerosis may
be due to pregnancy unmasking of asymptomatic disease or
causing hyperﬁltration injury.
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Therapeutic Management
Therapeutic management of glomerular disease in-
cludes immunosuppression, angiotensin blockade,
antihypertensive treatment, and the management of
complications associated with CKD. For all women with
glomerular disease, pregnancy intention should be
discussed before prescription.
Immunosuppression
Safe and effective contraception should be advised and
made available for all women taking teratogenic
immunosuppression, including mycophenolate, meth-
otrexate, and cyclophosphamide. These drugs should
be avoided in all women who wish to conceive, as well
as in women who are at risk of unintended pregnancy.
Alternative immunosuppressants, which are consid-
ered safe in pregnancy, include steroids,82–85 calci-
neurin inhibitors,86,87 azathioprine,88–90 and the
immunomodulatory drug hydroxychloroquine.57,61
Substitution of teratogenic drugs should take place at
least 3 months in advance of pregnancy to allow an
appropriate period of washout, and to establish disease
stability on alternate agents. Tacrolimus is an effective
treatment for lupus nephritis91 in uncontrolled
studies,92–94 including pregnancy,95 small randomized
trials,96,97 and meta-analyses.98 Although mycopheno-
late predominates in the management of lupus nephritis
outside of pregnancy, it should be remembered that
tacrolimus is a valid and safe option during pregnancy,
and for women who wish to conceive. Rituximab is
actively transported across the placenta during the
second and third trimesters. Although use is not
associated with congenital malformations, neonatal B-
cell depletion can occur, and long-term pediatric out-
comes are unknown.99 Manufacturers therefore
recommend avoiding pregnancy for 12 months after
exposure. However, rituximab may be the only effec-
tive therapy for some women with glomerular disease.
For such women, the beneﬁt of controlling active dis-
ease in pregnancy must be weighed against the risk of
exposure. Use of rituximab immediately before preg-
nancy or in the ﬁrst trimester minimizes fetal exposure
and the possibility of neonatal B-cell depletion. Live
vaccines (Bacillus Calmette–Guérin, rotavirus, varicella)
should be avoided for at least 6 months in infants
exposed to rituximab in utero.
Angiotensin Blockade and Antihypertension
Treatment
Angiotensin blockade is fetotoxic in the second and
third trimesters, causing oligohydramnios and neonatal
renal failure. However, population data regarding
angiotensin-converting enzyme inhibitor exposure in
the ﬁrst trimester, when corrected for hypertension
and diabetes, shows no increase in the rate of
congenital abnormality.100,101 For this reason,
angiotensin-converting enzyme inhibitors can be
continued if indicated for glomerular disease until a
diagnosis of pregnancy is made, with regular preg-
nancy testing advocated in women with irregular
menstrual cycles. Labetalol, nifedipine, and methyl-
dopa can be safely used for the management of hy-
pertension in pregnancy. Safety data for amlodipine are
lacking, but isolated case reports and small cohorts
show no evidence of harm.102–104
Complications of CKD
Anaemia is often multifactorial in women with
glomerular disease, including iron deﬁciency exacer-
bated by menstrual blood loss and impaired renal
synthesis of erythropoietin in CKD. Both oral and
intravenous iron105–109 can be given in pregnancy. The
physiological demands for erythropoietin are increased
in pregnancy, and gestational use of synthetic eryth-
ropoietin may be required at a higher level of renal
function than in nonpregnant women. Low-dose
aspirin for primary and secondary prevention of
vascular disease can be continued in pregnancy, and
should be commenced for preeclampsia prophylaxis for
all women with glomerular disease (see previously).
Vitamin D deﬁciency is common in pregnancy.110 In
addition, there is a physiological increase in calcitriol
(1,25[OH]2-vitamin D) production. For women with
renal disease, it is unknown how much this depends on
1-alpha hydroxylase activity in the kidney. In
the absence of better evidence, vitamin D replacement
should be given if serum calcifediol is <20 ng/ml
(50 nmol/l) with continuation of activated forms of
vitamin D at the appropriate pre-pregnancy dose.12
Cinacalcet in pregnancy is discontinued due to insuf-
ﬁcient safety data. Systematic review data show that
statins are not associated with congenital malforma-
tion,111 although increased rates of pregnancy loss are
reported.112 Current practice is therefore to discontinue
statin therapy for the duration of pregnancy. The
therapeutic use of hydrophilic statins (pravastatin) in
the amelioration of preeclampsia is the subject of
ongoing research.113
Lactation
Steroids, azathioprine, calcineurin inhibitors, hydrox-
ychloroquine, enalapril, captopril, labetalol, nifedipine,
atenolol, amlodipine, aspirin, and synthetic erythro-
poietin can all be continued during lactation. Up-to-
date safety data on speciﬁc drugs in breastfeeding is
available via the LactMed database (https://toxnet.nlm.
nih.gov/newtoxnet/lactmed.htm).
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Long-term Outcomes
There is a lack of consensus in published literature
about whether women have a better114,115 or worse116
prognosis in glomerular disease, compared with men.
Factors that are likely to contribute to this include
cohort heterogeneity, a failure to correct for con-
founding levels of blood pressure and proteinuria, the
historical use of creatinine measurement, which skews
the diagnosis of CKD toward men,117 and inaccuracies
in determining a change in estimated glomerular
ﬁltration rate when values are >60 ml/min per 1.73 m2.
A large cohort study found that women with mem-
branous nephropathy (n ¼ 395) and focal segmental
glomerulosclerosis (n ¼ 370) had a slower rate of
decline in renal function than men.6 Although this
effect was reduced when data were corrected for the
lower levels of proteinuria and blood pressure found in
women, there was still an apparent protective effect to
being female, with higher levels of proteinuria having
less effect on disease progression. However, in IgA
nephropathy, where there was no signiﬁcant difference
in proteinuria at presentation, there was no gender
disparity in rates of renal function decline and adverse
outcome.118
There is greater consensus in the long-term sequelae
attributable to the development of hypertensive preg-
nancy disorders and preeclampsia.Womenwho develop
preeclampsia have an increased risk future of hyper-
tension,119,120 cardiovascular events,121–124 and end-
stage renal disease.125 Large population studies show
that women with lupus and a history of preeclampsia
are at increased risk of later cardiovascular events,
Table 3. An overview of the impact of glomerular disease in women
Aspect of health Glomerular etiology Impact Details
Disease
prevalence
All Increased opportunities for
diagnosis in women
Higher use of primary care by women, with opportunities for urine and blood
pressure screening.
SLE Female preponderance Hypothesized modulation of immune system by sex steroids.
Preeclampsia Affects 3%–5% of women Estimated to be the most common glomerular disease worldwide. Prevalence
underestimated by histological data as biopsy is rare.
Fertility All Reduced Effects of CKD on reproductive hormone proﬁle. Voluntary childlessness may
contribute.
SLE Reduced Active disease, anti–corpus luteum antibodies, endometriosis, reduced ovarian
reserve.
SLE, vasculitis, rapidly progressive
GN
Reduced Dose- and age-dependent premature ovarian failure secondary to
cyclophosphamide. Consider fertility preservation in premenopausal
women.
All Need for artiﬁcial reproductive
techniques
Risk of VTE and ovarian hyperstimulation.
Single-embryo transfer in CKD.
Contraception All Required with teratogenic
medication
Includes mycophenolate, cyclophosphamide, methotrexate.
Progesterone-only preparations are safe and effective in SLE and CKD.
Pregnancy All Remove teratogens in advance of
pregnancy
Advise 3 months for washout and to ensure disease stability. CNI, Aza, HCQ,
steroids are considered safe for pregnancy.
All Adverse pregnancy outcomes Increased risk with CKD, hypertension, and proteinuria.
All Preeclampsia Prophylaxis with low-dose aspirin (75–150 mg).
No diagnostic criteria for superimposed preeclampsia. Clinical overlap with GN
signs and symptoms. Surveillance by an expert clinical team.
Future use of anti/angiogenic biomarkers predicted.
All VTE risk in pregnancy increased if
proteinuria
Threshold for LMWH prophylaxis unknown.
All BP Aim <140/90 mm Hg.
All Vitamin D deﬁciency Replacement if 25-hydroxyvitamin D is <20 ng/ml (50 nmol/l). Continue
activated vitamin D analogs as pre-pregnancy.
All Anemia Increased erythropoietin requirement. May need synthetic replacement.
All relapsing-remitting GN Disease activity associated with
adverse pregnancy outcome
Aim remission for 6 months before conception.
HCQ for all women with lupus nephritis.
SLE Risk of ﬂare Risk of w15% during pregnancy and w15% in 1-year postpartum.
SLE Placental transfer of maternal
antibodies
Risk of neonatal cutaneous lupus and congenital heart block with anti SSA
(Ro)/SSB (La).
Thromboprophylaxis in antiphospholipid syndrome.
Membranous anti-PLA2R Role in maternal diagnosis/prognosis and fetal effects unknown.
Long-term
outcomes
Membranous and FSGS Slower rate of decline in renal
function
Lower levels of BP and proteinuria in women contribute. Additional protective
effect also measured in women.
All with a history of preeclampsia Increased future vascular and renal
disease risk
Causality versus association not determined.
IgA Renal disease progression Not affected by pregnancy if renal function preserved.
AZA, azathioprine; BP, blood pressure; CKD, chronic kidney disease; CNI, calcineurin inhibitor; FSGS, focal segmental glomerulosclerosis; GN, glomerulonephritis; HCQ, hydroxy-
chloroquine; PLA2R, anti–phospholipase A2 receptor antibodies; LMWH, low molecular weight heparin; SLE, systemic lupus erythematosus; SSA/SSB, Sjögren syndrome antibodies; VTE,
venous thromboembolism.
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including mortality.126 However, the impact of
increased postpregnancy surveillance in these pop-
ulations and the beneﬁts of primary prevention are un-
known. For womenwith glomerular disease, it is unclear
whether the development of preeclampsia is an inde-
pendent risk factor for long-term renal disease progres-
sion, or whether preeclampsia is a surrogate marker of
underlying renal disease severity. Retrospective data
reveal that a combination of pregnancy outcome,
including preeclampsia, preterm delivery, and low
birthweight, is associated with accelerated loss of renal
function over 3 to 10 years in women with IgA ne-
phropathy onlywhen the estimated glomerularﬁltration
rate is <60 ml/min per 1.73 m2, or if there is coexisting
hypertension or proteinuria >1 g per day.127
Conversely, cohort studies128,129 and a meta-analysis130
show that for women with IgA nephropathy who
approximate to CKD Stages 1 and 2, there is no difference
in renal disease progression between women who un-
dertake a pregnancy compared with those who do not.
Women with IgA nephropathy who have an uncom-
plicated pregnancy course have been found to have a
good renal prognosis, even compared with women who
do not undergo a pregnancy following diagnosis.127
Conclusions
Glomerular disease in women affects fertility, contra-
ceptive options, and pregnancy outcome, and may
modify disease progression, especially in the context of
preeclampsia (Table 3). Lupus predominates in pub-
lished literature and has extra considerations for
reproductive health depending on the associated anti-
body proﬁle. There are fewer disease-speciﬁc data for
other glomerular etiologies. Pregnancy should be plan-
ned for all women with glomerular disease to ensure
disease quiescence/stability. Cyclophosphamide, myco-
phenolate, and methotrexate are teratogenic and should
be avoided in women with glomerular disease who wish
to conceive, or who are at risk of an unintended preg-
nancy. Impaired renal function, hypertension, and
proteinuria are consistently associated with adverse
pregnancy outcome, irrespective of the underlying
glomerular etiology. Glomerular disease can mimic
preeclampsia, but renal biopsy in late pregnancy is
relatively high risk. An important future role for
angiogenic biomarkers in the discrimination between
glomerular disease and preeclampsia is predicted.
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